Navigation Links
Rapid growth may be appropriate trigger for treatment in patients with renal masses
Date:5/16/2011

WASHINGTON, D.C. (May 15, 2011)With an increase in abdominal imaging over the past decade, there has been an increase in the detection of incidental kidney cancer, which has led to concerns that we may be over-treating indolent disease. As part of this effort, clinicians have started to investigate the effectiveness of active surveillance (AS), or close observation as opposed to immediate surgery, for select patients with small renal masses (SRMs). Today, Fox Chase Cancer Center researchers will announce the results of its systematic review and pooled analysis, which for the first time combined several institutions' experience with active surveillance of small renal masses. Their goal was to identify trends in radiographic tumor growth rates and progression to either treatment or metastasis, and found that in select patients, active surveillance may be a viable option when surgery is risky due to poor health or advanced age.

Marc Smaldone, M.D., urologic oncology fellow at Fox Chase and lead author on the study, will present the results at the AUA 2011 Annual Meeting on Tuesday, May 17, 2011.

"Kidney cancer is most often a surgically treated disease, so studies such as this one, which help to confirm that active surveillance with curative intent can be an effective strategy for certain patients, are crucial," says Smaldone. "Surgery has substantial consequences for many patients with competing risks such as heart or lung disease. The ability to offer a management strategy that avoids the risks of potentially unnecessary surgery is an attractive concept in contemporary cancer treatment."

To further investigate the risks of cancer progression in patients undergoing active surveillance, Fox Chase researchers combined all the available individual data published by institutions examining the observation of small renal masses. The team identified and pooled a total of 18 institutional series, of which Fox Chase's experience represented the largest published series. The researchers then examined the pooled experience for trends in radiographic growth rates, tumor size at presentation, and progression to treatment or metastasis.

They found that, of the observed 936 SRMs in 880 patients, only a very small proportion 2.1% (18 patients) progressed to metastasis. Pooled analysis of progressors and non-progressors revealed significant trends including increased age, increased tumor size at presentation, and increased growth rates in the progression group. These metrics can be used to help determine if a patient should stop surveillance and undergo surgical intervention for his or her SRM. However, Fox Chase researchers learned that growth kinetics alone cannot predict a tumor's natural growth history. Therefore, active surveillance should not be considered an equivalent alternative to definitive surgical therapy, but it can be used as an initial short-term option for select patients who are poor surgical candidates.

"There is a perception that all cancers, once detected, should be treated immediately because they are all equally lethal, but what we've seen in this study is that small, asymptomatic kidney cancers can be managed through active surveillance," says Robert G. Uzzo, M.D., F.A.C.S., chairman of the department of surgery at Fox Chase and member of the AUA Guidelines Council. "As a medical community, we need to recognize this shift and begin to risk stratify patients and counsel them based on criteria other than the presence of small renal masses on scans."

While more research is necessary, this study suggests that growth kinetics may be the best measurement currently available for determining which patients should undergo immediate intervention and which should not. As a supplement to radiographic data, future biomarker discovery in conjunction with percutaneous or renal biopsy might ultimately influence management decisions on an individual patient basis. Based on these findings patients should seek out urologic oncology experts to help them understand the implications of small kidney cancers and avoid overtreatment.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
2. Rapid Flu Test Most Accurate for Young Kids
3. Artists, Product Designers, Printing Gurus, Game Developers, Manufacturing Engineers Will Converge at RAPID 2010/3D IMAGING Conference/Expo, May 18-20 in LA
4. Aspirus Eases Pain of Rapid Data Growth With an EMC Information Infrastructure
5. A new generation of rapid-acting antidepressants?
6. Rapid development of drug-resistant 2009 H1N1 influenza reported in 2 cases
7. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
8. RapidValue Launches iPad Application Development Services for Media & Publishing Firms
9. Non-medical treatment may rapidly relieve severe IBS symptoms
10. Nonmedical treatment may rapidly relieve severe IBS symptoms
11. Rapid analysis of DNA damage now possible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... July 28, 2017 , ... Shamanic Teacher Anahata Ananda of ... is proud to announce the return of her increasingly popular “Shamanic Wisdom ... more about the mystical world of shamanism, nature wisdom, the medicine wheel, energy ...
(Date:7/27/2017)... ... July 27, 2017 , ... Dr. ... Board of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing an extensive two-day examination ... of dental implants . Dr. Kimowitz and his partner Dr. Hal Kimowitz, ...
(Date:7/27/2017)... Longview, TX (PRWEB) , ... July 27, 2017 ... ... to receive a new set of teeth in a single office visit from ... convenient and comfortable treatment solutions to his East Texas patients, including Teeth-in-a-Day® ...
(Date:7/27/2017)... ... July 28, 2017 , ... DMG Productions is pleased to ... television series, American Famer, scheduled to broadcast fourth quarter 2017. American Farmer airs ... helping humanity face its toughest challenge: how to feed a rising population in ...
(Date:7/27/2017)... ... 27, 2017 , ... SSCI, a division of Albany Molecular ... worldwide, representing a milestone achievement. , As an industry-leading provider of ... have served as expert and fact witnesses to assist our clients to perform ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone ... the midst of a crippling opioid epidemic. According to the ... of overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... dead from 2001 to 2015". During this time, the prescription ... quadrupled, drawing a compelling link between prescription and eventual addiction. ...
(Date:7/12/2017)... July 12, 2017  Eli Lilly and Company (NYSE: ... generic companies to resolve pending patent litigation in the U.S. ... regarding the Cialis ® (tadalafil) unit dose ... 26, 2020. As part of the agreement, Cialis exclusivity is ... 2018. "The unit dose patent for Cialis is ...
Breaking Medicine Technology: